Abstract
Cancer patients, though frequently entering complete remission after successful surgery, and/or irradiation, and chemotherapy years or even decades later may exhibit overt metastases and aggressive, mostly fatal recurrence on the basis of clinically silent persistence of disseminated tumor cells. Cellular dormancy is a mode of hibernation/ inactivity caused by a temporary mitotic arrest. It represents the critical phenomenon of latency making metastatic cancer cells highly refractory to conventional therapies. Regarding host-tumor interactions a broad range of dynamic, interrelated molecular events may influence the dormancy state of quiescence, like regulators of cell cycle arrest, stress signaling pathways, autophagy, microenvironmental, angiogenic and immunologic factors, genetic and epigenetic effects. Nonetheless, the underlying mechanisms are still poorly understood. Moreover, a distinct subset of circulating and disseminated cancer cells exhibits stem cell-like properties with direct tumor-provoking and metastatis-initiating capacity, being at least partly responsible for the specific dormancy features. In residual disease a future more detailed molecular and phenotypic characterization of disseminated tumor cells could represent the prerequisite not only for prognostic and staging purposes, but for a specific design of therapeutic targeting, as well. By understanding the elusive dormancy signatures of tumor cells, their cell- and context (microenvironment)-dependent modulation should provide novel potential therapeutic approaches to avoid or overcome metastatic cancer relapse.
Keywords: Cancer dormancy, metastasis, stress signals, cell adaptation, quiescence, autophagy, microenvironment, stem cell.
Anti-Cancer Agents in Medicinal Chemistry
Title:Metastatic Cell Dormancy and Re-activation: An Overview on Series of Molecular Events Critical for Cancer Relapse
Volume: 17 Issue: 4
Author(s): Gyorgyi Muzes*Ferenc Sipos
Affiliation:
- 2nd Department of Internal Medicine, Semmelweis University, H-1088 Budapest, Szentkirályi str. 46.,Hungary
Keywords: Cancer dormancy, metastasis, stress signals, cell adaptation, quiescence, autophagy, microenvironment, stem cell.
Abstract: Cancer patients, though frequently entering complete remission after successful surgery, and/or irradiation, and chemotherapy years or even decades later may exhibit overt metastases and aggressive, mostly fatal recurrence on the basis of clinically silent persistence of disseminated tumor cells. Cellular dormancy is a mode of hibernation/ inactivity caused by a temporary mitotic arrest. It represents the critical phenomenon of latency making metastatic cancer cells highly refractory to conventional therapies. Regarding host-tumor interactions a broad range of dynamic, interrelated molecular events may influence the dormancy state of quiescence, like regulators of cell cycle arrest, stress signaling pathways, autophagy, microenvironmental, angiogenic and immunologic factors, genetic and epigenetic effects. Nonetheless, the underlying mechanisms are still poorly understood. Moreover, a distinct subset of circulating and disseminated cancer cells exhibits stem cell-like properties with direct tumor-provoking and metastatis-initiating capacity, being at least partly responsible for the specific dormancy features. In residual disease a future more detailed molecular and phenotypic characterization of disseminated tumor cells could represent the prerequisite not only for prognostic and staging purposes, but for a specific design of therapeutic targeting, as well. By understanding the elusive dormancy signatures of tumor cells, their cell- and context (microenvironment)-dependent modulation should provide novel potential therapeutic approaches to avoid or overcome metastatic cancer relapse.
Export Options
About this article
Cite this article as:
Muzes Gyorgyi*, Sipos Ferenc, Metastatic Cell Dormancy and Re-activation: An Overview on Series of Molecular Events Critical for Cancer Relapse, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (4) . https://dx.doi.org/10.2174/1871520616666160901145857
DOI https://dx.doi.org/10.2174/1871520616666160901145857 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Discovery of Lead compounds targeting transcriptional regulation
Transcriptional regulation plays key physiological functions in body growth and development. Transcriptional dysregulation is one of important biomarkers of tumor genesis and progression, which is involved in regulating tumor cell processes such as cell proliferation, differentiation, and apoptosis. Additionally, it plays a pivotal role in angiogenesis and promotes tumor metastasis ...read more
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Innovative targets in medicinal chemistry
Medicinal chemistry continuously evolves in response to emerging healthcare needs and advancements in scientific understanding. This special issue explores the current landscape of innovative targets in medicinal chemistry, highlighting the quest for novel therapeutic avenues. From traditional drug targets such as enzymes and receptors to emerging targets like protein-protein interactions ...read more
Metalloenzymes and Cancer: Μetalloenzyme Ιnhibitors and Artificial Metalloenzymes as anti-cancer agents
Metalloenzymes are enzymes containing metal ions, which are directly bound to the enzyme and play a role in promoting catalysis. About one-third of all enzymes known so far are metalloenzymes [1]. Metalloenzymes are central to a wide range of essential biological activities, including nucleic acid modification, protein degradation, and many ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hybrid Magnetic Nanostructures For Cancer Diagnosis And Therapy
Anti-Cancer Agents in Medicinal Chemistry Silencing Human Cancer: Identification and Uses of MicroRNAs
Recent Patents on Anti-Cancer Drug Discovery Cancer and Stem Cells
Current Cancer Therapy Reviews Malignant Mesothelioma: Cell Survival Pathways and Radiation Therapy
Current Respiratory Medicine Reviews Curcumin and its Formulations: Potential Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Cancer Stem Cells in Pediatric Brain Tumors
Current Stem Cell Research & Therapy Classification of Sarcomas Using Bioinformatics and Molecular Profiling
Current Pharmaceutical Biotechnology In Situ Gene Therapy for Prostate Cancer
Current Gene Therapy Alkylphospholipids are Signal Transduction Modulators with Potential for Anticancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Differentiation-Inducing Therapy for Solid Tumors
Current Pharmaceutical Design Cell Penetrating Peptides as a Therapeutic Strategy in Chronic Lymphocytic Leukemia
Protein & Peptide Letters A Closer Look at Protein Transduction Domains as a Tool in Drug Delivery
Current Nanoscience Cell-Penetrating Peptides: Mechanisms and Applications
Current Pharmaceutical Design Prostate Cancer Gene Expression Marker 1 (PCGEM1): A Patented Prostate- Specific Non-Coding Gene and Regulator of Prostate Cancer Progression
Recent Patents on DNA & Gene Sequences Targeted Cancer Stem Cell Therapeutics: An Update
Current Topics in Medicinal Chemistry Protein-Protein Interactions: Lessons Learned
Current Medicinal Chemistry - Anti-Cancer Agents Immunokinases, a Novel Class of Immunotherapeutics for Targeted Cancer Therapy
Current Pharmaceutical Design Novel Antitumor Strategies Using Cytokine PEDF for Prostate Cancer Therapy
Current Angiogenesis (Discontinued) Impact of Splicing Factor Mutations on Pre-mRNA Splicing in the Myelodysplastic Syndromes
Current Pharmaceutical Design DNA Methylation and Breast Cancer
Current Genomics